Payment overview · 2025
General Payments
$1,925.41
35 reported records · 11 companies
Healthcare provider profile · identity verified
Amit Bhalodia, D.O
Allopathic & Osteopathic Physicians|Family Medicine · CAMDEN, NJ · NPI 1982692083
Verified facts
What the public records show
CMS Open Payments records show Amit Bhalodia, D.O received $1,925.41 in general payments during 2025 across 35 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 69.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $1,344.56 | 69.8% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $119.53 | 6.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $99.17 | 5.2% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $94.41 | 4.9% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $60.70 | 3.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $50.66 | 2.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $44.30 | 2.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.98 | 1.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.86 | 1.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.34 | 1.3% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $18.90 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $1,090.34 | 4 |
| Food and Beverage | $835.07 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $119.53 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $119.53 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $94.41 | 5 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $65.40 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $60.70 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $44.30 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $44.30 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $36.98 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $36.98 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $36.98 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $33.77 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.59 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.59 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $24.34 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $18.90 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 69 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 110 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 58 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
69 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
110 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
110 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
49 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 685 | 159 |
| Amlodipine Besylate | Amlodipine Besylate | 548 | 131 |
| Metformin Hcl | Metformin Hcl | 330 | 70 |
| Lisinopril | Lisinopril | 273 | 72 |
| Losartan Potassium | Losartan Potassium | 262 | 62 |
| Omeprazole | Omeprazole | 249 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 235 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 235 | 53 |
| Levothyroxine Sodium | Levothyroxine Sodium | 178 | 40 |
| Carvedilol | Carvedilol | 175 | 43 |
| Gabapentin | Gabapentin | 171 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 153 | 34 |
| Famotidine | Famotidine | 150 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 136 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 127 | 16 |
| Montelukast Sodium | Montelukast Sodium | 114 | 27 |
| Jardiance | Empagliflozin | 110 | 22 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 108 | 39 |
| Januvia | Sitagliptin Phosphate | 104 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 104 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 103 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 97 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 97 | 29 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 84 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 84 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 81 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 74 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 74 | 17 |
| Furosemide | Furosemide | 73 | 20 |
| Farxiga | Dapagliflozin Propanediol | 69 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | 21 |
| Buspirone Hcl | Buspirone Hcl | 65 | 14 |
| Glipizide Er | Glipizide | 61 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 60 | 17 |
| Ozempic | Semaglutide | 58 | suppressed |
| Allopurinol | Allopurinol | 57 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | suppressed |
| Glipizide | Glipizide | 50 | 13 |
| Eliquis | Apixaban | 49 | 12 |
| Glimepiride | Glimepiride | 49 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 44 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 43 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 41 | suppressed |
| Ezetimibe | Ezetimibe | 41 | suppressed |
| Spironolactone | Spironolactone | 41 | suppressed |
| Alprazolam | Alprazolam | 38 | suppressed |
| Linzess | Linaclotide | 36 | suppressed |
| Lovastatin | Lovastatin | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Valsartan | Valsartan | 36 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | 11 |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Potassium Chloride | Potassium Chloride | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 32 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 31 | suppressed |
| Repaglinide | Repaglinide | 30 | suppressed |
| Torsemide | Torsemide | 30 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Cilostazol | Cilostazol | 27 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 25 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 24 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 21 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | 11 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 14 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Simvastatin | Simvastatin | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Menest | Estrogens,esterified | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,925.41 · 35 records | Boehringer Ingelheim Pharmaceuticals, Inc. | ABRYSVO, AIRSUPRA, COMIRNATY, Cologuard Collection Kit, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, MOUNJARO, Ohtuvayre, Ozempic, PREVNAR 20, QULIPTA, RELISTOR, Rybelsus, UBRELVY, VOQUEZNA, XIFAXAN, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error